Response by Hänggi and Macdonald to Letter Regarding Article, “Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Professor Rustemi for his insightful comments on the NEWTON study (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage).1 This study included standard-of-care control subjects who received enteral nimodipine. Intravenous nimodipine was not used because it is not available in the United States and Canada, whereas enteral nimodipine is available in most countries worldwide. Meta-analysis of nimodipine randomized trials reported that the efficacy of nimodipine was based on the enteral formulation and that there was insufficient evidence to support the efficacy of intravenous nimodipine.2 Therefore, standard-of-care control subjects in NEWTON received enteral nimodipine.1, …